Firefly Neuroscience (AIFF) shares were up more than 170% in recent trading after the company said it was accepted into the Nvidia (NVDA) Connect program.
Intraday trading volume catapulted to over 155 million shares from a daily average of about 2.48 million.
Lipella Pharmaceuticals (LIPO) said its treatment candidate for oral lichen planus showed "clinically meaningful" reductions in pain, ulceration, and inflammation across all key metrics in a phase 2a trial.
Shares soared about 36% as intraday trading volume surged to over 37.2 million from a daily average of about 1.59 million.
Travere Therapeutics (TVTX) said it completed a meeting with the US Food and Drug Administration and plans to submit a supplemental new drug application for approval of Filspari for focal segmental glomerulosclerosis, a rare kidney disorder.
Wedbush raised its price target on the stock to $30 from $26 while maintaining its outperform rating.
Shares of Travere rose 13% as intraday trading volume climbed to over 3.62 million from a daily average of about 1.29 million.
Price: 8.01, Change: +4.91, Percent Change: +158.39
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。